The Patent Finder

Mesoblast International Sàrl

28 patents currently held · Updated Nov 20, 2026
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 3 name spellings.

4
Ending by 2030
Jan 2027
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 27, 2026
    The maintenance fee for Cell Culture Method for Mesenchymal Stem Cells (US 11,685,899) comes due Dec 27, 2026. Unpaid by Jun 28, 2027, it lapses early.
  • 1 fee due Feb 1, 2027
    The maintenance fee for Method for Treating Heart Failure (US 11,712,452) comes due Feb 1, 2027. Unpaid by Aug 2, 2027, it lapses early.
  • 1 fee due Mar 3, 2027
    The maintenance fee for Improved Stem Cell Composition (US 10,400,218) comes due Mar 3, 2027. Unpaid by Sep 3, 2027, it lapses early.
  • 2 fees due Apr 24 to 29, 2027 · next Apr 24
  • 1 fee due Aug 4, 2027
    The maintenance fee for Enhanced MSC Preparation (US 10,550,369) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
  • 2 fees due Oct 12 to 21, 2027 · next Oct 12

Which patents, and when each one lapses · Pro

Recent changes

  • 1 term has ended since Aug 22, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,486,695Mesenchymal Stem Cells Expressing TNF-alpha Receptors
In force
 · High confidence
In forceHigh confidence
US 11,821,004Mesenchymal Stem Cells Expressing TNF-alpha Receptors
In force
 · High confidence
In forceHigh confidence
US 7,696,309Protease Resistant Mutants of Stromal Cell Derived FACTOR-1 in the Repair of Tissue Damage
In force
 · High confidence
In forceHigh confidence
US 7,999,067Protease Resistant Mutants of Stromal Cell Derived FACTOR-1 in the Repair of Tissue Damage
In force
 · High confidence
In forceHigh confidence
US 10,456,451Protease-Resistant Mutants of Stromal Cell Derived FACTOR-1 in the Repair of Tissue Damage
In force
 · High confidence
In forceHigh confidence
US 9,828,586Enhanced MSC Preparations
In force
 · Medium confidence
In forceMedium confidence
US 9,963,678Enhanced MSC Preparations
In force
 · Low confidence
In forceLow confidence
US 11,708,560Enhanced MSC Preparations
In force
 · Low confidence
In forceLow confidence
US 12,410,405Enhanced MSC Preparations
In force
 · High confidence
In forceHigh confidence
US 9,308,277Protease-Resistant Mutants of Stromal Cell Derived FACTOR-1 in the Repair of Tissue Damage
In force
 · High confidence
In forceHigh confidence
10 of 28 patents shown.
Pro members see all 28.
Pro members: see all 28 patents
Also on record, not counted in the 28: 3 lapsed for an unpaid fee · 54 ended at full term. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

16 pending · 19 abandoned · 3 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited